|
Stabilized coronavirus spike proteins for enhanced vaccine efficacy
Engineered proteins with stabilized coronavirus spike protein ectodomains enhance immune response and are useful in diagnostics, screening, and vaccines against coronaviruses like SARS-CoV-2 by maintaining prefusion conformation, potentially producing cross-reactive antibodies.
Background
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has...
|
|
Engineered chimeric fusion proteins
Enhancing stability and expression for improved vaccines and diagnostics in hMPV and RSV
The invention describes engineered chimeric F proteins combining sequences from human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) to enhance stability and expression. These proteins are useful in vaccines, diagnostics, and antibody screening.
Background
Respiratory...
|
|
Monoclonal antibodies for the conserved feature of the coronavirus spike protein
The invention describes monoclonal antibodies targeting conserved epitopes on the S2 domain of coronavirus spike proteins, potentially useful for preventing or treating infections by inhibiting viral entry. These antibodies could aid in therapeutic formulations against coronaviruses like SARS-CoV-2, SARS-CoV, and MERS-CoV.
Background
The emergence...
|
|
Producing modified lipid A bacterial vaccine components
Engineered bacteria are designed to produce modified lipid A with reduced toxicity and either polypeptide or polysaccharide antigens, which can be used in vaccines to elicit targeted immune responses.
Background
The challenge of developing effective vaccines against bacterial infections lies in the dual necessity of eliciting a robust immune response...
|
|
Engineered polypeptides for enhanced integrin binding and antigen delivery
Engineered recombinant Invasin polypeptides have been modified to enhance integrin binding and resist intestinal proteolysis, facilitating effective oral delivery of therapeutics, such as vaccines, by targeting M cells in the gut for improved immune responses.
Background
The challenge of delivering therapeutics such as vaccines effectively across...
|
|
Treating respiratory diseases and whooping cough
This technology involves compositions and methods for treating respiratory diseases like whooping cough and includes immunization techniques.
Background
The field of respiratory disease treatment and immunization is important due to the significant health burden posed by conditions such as whooping cough. Whooping cough, or pertussis, is a highly...
|
|
One and done: A variant-proof coronavirus vaccine
Background/problem
Coronaviruses, including SARS-CoV-2, caused the COVID-19 pandemic of plague-like infectiousness with >770 M cases and 6.9M deaths worldwide. Vaccination provided protection against severe disease progression, hospitalization, and mortality. However, current vaccine technology is in an arms race against the continual evolution...
|
|
Broadly neutralizing human mAbs targeting the SARS‑CoV‑2 spike protein
Problem
Monoclonal antibodies (mAbs) that target the SARS-CoV-2 spike protein have been shown to have clinical benefits in the treatment of SARS-CoV-2 infection. The activity of anti-SARS-CoV-2 mAbs against specific variants and subvariants of this virus can vary dramatically. There is a clinical need for continued identification of anti-SARS-CoV-2...
|
